HD-OPM Archive
Topics › Weight, visceral & liver fat

Mayo Clinic: senescent cells drive inflammation in severe fatty liver disease (MASH)

Louis Nervegna · Dec 17, 2025 · ♥ 5 reactions · 4 comments · original Facebook post
Weight, visceral & liver fatInflammation & CRPAging & longevity
AI summary & key facts

Louis shares a Mayo Clinic report that senescent 'zombie' cells trigger inflammation that accelerates MASH, and speculates that senolytic drugs or supplements could be tested. The post is a news summary of mechanistic research with no trial data.

Senescent cells seem to play a major role in progression of severe fatty liver disease, according to new research at the Mayo Clinic.

Drugs and supplements called senolytics that kill these senescent cells might be useful in treating this disease. We will likely see clinical trials on this soon.

#senolyticsHD #fattyliverHD #mayoclinicHD #mashHD #senescenceHD

Research cited

Shared from Mayo Clinic · original post

A new Mayo Clinic study shows how aging "zombie" cells — also known as senescent cells — can trigger harmful inflammation that accelerates metabolic dysfunction‑associated steatohepatitis (MASH), a severe form of fatty liver disease. As obesity rises worldwide, MASH is increasing and is already one of the leading reasons for liver transplantation.

"Liver scarring and inflammation are hallmarks of MASH. If left untreated, it can progress to liver cancer. This is why it's so important to understand the mechanisms driving the disease so that we can prevent it or develop more effective treatments," says lead author Stella Victorelli, Ph.D.

Read more:

newsnetwork.mayoclinic.orgZombie cells spark inflammation in severe fatty liver disease mayo clinic researchers findmayocl.inNo photo description available.
← newer: 100+ feeding trials: polyunsaturated fat improves glucose coolder: Uterine fibroids linked to over 80% higher long-term heart d →